Christopher Benecchi
Corporate Officer/Principal presso SAGE THERAPEUTICS, INC.
Patrimonio netto: 364 118 $ in data 31/03/2024
Profilo
Christopher Benecchi is currently the Chief Business Officer at SAGE Therapeutics, Inc. Prior to his current position, he served as the Vice President & Global Head-Commercial Excellence at Alexion Pharmaceuticals, Inc. from 2019 to 2021.
Before that, he was the Global Launch Head-Commercial & Medical Affairs at UCB, Inc. from 2011 to 2019.
Mr. Benecchi holds an MBA from Duke University and completed his undergraduate studies at Colby College.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
SAGE THERAPEUTICS, INC.
0.03% | 13/02/2024 | 19 430 ( 0.03% ) | 364 118 $ | 31/03/2024 |
Posizioni attive di Christopher Benecchi
| Società | Posizione | Inizio |
|---|---|---|
| SAGE THERAPEUTICS, INC. | Corporate Officer/Principal | 21/09/2021 |
Precedenti posizioni note di Christopher Benecchi
| Società | Posizione | Fine |
|---|---|---|
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/09/2021 |
UCB, Inc.
 UCB, Inc. Financial ConglomeratesFinance Part of UCB SA, UCB, Inc. provides financial services. The private company is based in Smyrna, GA. The CEO of the company is Duane Barnes. | Corporate Officer/Principal | 01/08/2019 |
Formazione di Christopher Benecchi
| Duke University | Masters Business Admin |
| Colby College | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| SAGE THERAPEUTICS, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
UCB, Inc.
UCB, Inc. Financial ConglomeratesFinance Part of UCB SA, UCB, Inc. provides financial services. The private company is based in Smyrna, GA. The CEO of the company is Duane Barnes. | Finance |
- Borsa valori
- Insiders
- Christopher Benecchi
